-
Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Fredrik N Albach,Ioanna Minopoulou,Artur Wilhelm,Robert Biesen,Arnd Kleyer,Edgar Wiebe,Anja Fleischmann,Mareike Frick,Frederik Damm,Julia Gogolok,Sebastian Serve,Benjamin Nick Locher,Dominic Borie,Vincent Casteleyn,Elise Siegert,Thomas Dörner,Tobias Alexander,Christian Furth,Jan Zernicke,Kamran Movassaghi,Marie Luise Hütter-Krönke,Eva Schrezenmeier,Udo Schneider,Lars Bullinger,Gerhard Krönke,Olaf Penack
-
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Matthew A Sherman,Rebecca Nicolai,Emily K Datyner,Silvia Rosina,Angela Hamilton,Kaveh Ardalan,Brigitte Bader-Meunier,Amanda G Brown,Marc H A Jansen,Susan Kim,Bianca Lang,Raquel Campanilho-Marques,Liza J McCann,Helga Sanner,Saskia R Veldkamp,Meredyth G Ll Wilkinson,Belina Y Yi,Hanna Kim,Stacey E Tarvin,Charalampia Papadopoulou,
OBJECTIVES Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory juvenile dermatomyositis (JDM). However, JAKi remains an off-label treatment for JDM and there may be variation in use worldwide. An international survey
-
Association of anti-eukaryotic initiation factor 2B with rapidly progressing interstitial lung disease: a case presentation. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Gideon Haffenden,Myles J Lewis,Gavin Thomas,Richard Toshner
-
Global ultrasound synovitis scores reflect symptom severity and patient outcomes in chronic chikungunya disease. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Hugh Watson,Juana Del Valle-Mendoza,Miguel Angel Aguilar-Luis,Ronald Aquino-Ortega,Wilmer Silva-Caso,Yordi Tarazona-Castro,Andrea Nizzardo,Giulia Calusi,Marie Mandron,Esteban Puentes,Christine Luxemburger,Maria Antonietta D'Agostino
OBJECTIVES Acute chikungunya virus infection often leads to chronic post-infection arthritis, but investigation and evaluation of treatment is hampered by the subjectivity of symptoms. This study was designed to evaluate ultrasound scores and serum inflammatory markers as objective measures for the severity of chronic post-chikungunya arthritis. METHODS Patients with acute chikungunya virus infection
-
Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Shyfuddin Ahmed,Ruth M Pfeiffer,Sarah S Jackson,Minkyo Song,Xavier Mariette,Raphaele Seror,Eric A Engels
OBJECTIVE To examine cancer risk associated with Janus kinase inhibitors (JAKis) and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA). METHODS Case-control study of patients with RA age 65 years or older in the United States Surveillance, Epidemiology, and End Results (SEER)-Medicare database during 2014-2019. Cases were individuals with a first
-
Obesity reduces the urate-lowering efficacy among patients with primary gout: a prospective cohort study. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Zan Cheng,Xinmiao Xu,Han Qi,Xiaoyu Li,Yushuang Li,Chang Jiang,Xinyuan Miao,Xiaopeng Ji,Yunyang Wang,Bingzi Dong,Changgui Li,Jie Lu
OBJECTIVES Obesity affects 53% of gout patients, while its effect on urate-lowering therapy (ULT) is unclear. This study aimed to compare the response to febuxostat among different body mass index (BMI) catalogs of male gout patients. METHODS A prospective study recruited 633 men with gout, classified by BMI into normal-weight, overweight, and obese groups. Baseline age, disease duration, and serum
-
Corticosteroid use in PFAPA syndrome: clinical practice data from the JIR-CliPS Survey Study and a comprehensive literature review. Rheumatology (IF 4.7) Pub Date : 2025-02-10 Ezgi Deniz Batu,Seher Sener,Mariana Rodrigues,Caroline Vinit,Francois Hofer,Katerina Laskari,Ricardo Craveiro Costa,Margarida Santos Faria,Gulcan Ozomay Baykal,Oksana Boyarchuk,Olivier Gilliaux,Konstantinos Pateras,Hafize Emine Sonmez,Natasa Toplak,Marco Gattorno,Michaël Hofer
OBJECTIVES Corticosteroids are used to abort disease flares in PFAPA syndrome. We aimed to obtain a global overview of physicians' corticosteroid usage strategies and analyze the data in the literature regarding corticosteroid use in PFAPA syndrome. METHODS The JIR-CliPS PFAPA questionnaire included nine questions on corticosteroid use in addition to the demographic data questions. The survey was distributed
-
Comment on: Risk factors of COVID-19 related hospitalization of pediatric patients with rheumatic diseases: a systematic review and meta-analysis. Rheumatology (IF 4.7) Pub Date : 2025-02-08 Shubham Kumar,Ahmad Neyazi,Rachana Mehta,Ranjana Sah
-
Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry. Rheumatology (IF 4.7) Pub Date : 2025-02-07 Adrián Martín-Gutiérrez,Juan Molina-Collada,Marta Domínguez-Álvaro,Rafael B Melero-González,Elisa Fernández-Fernández,Maite Silva-Díaz,Jesús Alejandro Valero,Ismael González,Julio Sánchez Martín,Javier Narváez,Itziar Calvo,Vicente Aldasoro,Lydia Abasolo Alcázar,Javier Loricera,Alberto Ruíz-Roman,Santos Castañeda,Clara Molina-Almela,María Alcalde Villar,Antonio Juan Mas,Ricardo Blanco,
OBJECTIVE To determine the prevalence and predictive factors of cerebrovascular accidents (CVA) in giant cell arteritis (GCA). METHODS ARTESER is a large Spanish multicentre registry including patients with GCA from across the entire country diagnosed between June 2013 and March 2019 and sponsored by the Spanish Society of Rheumatology. The variables collected at diagnosis were demographics, clinical
-
Transarterial periarticular embolization (TAPE) in checkpoint-inhibitor-associated arthritis-a novel treatment strategy. Rheumatology (IF 4.7) Pub Date : 2025-02-07 Alexander Pfeil,Thoms Stauch,Carolin Pflug,Gunter Wolf,Ulf Teichgräber,René Aschenbach
-
CAPI-detect: machine learning in capillaroscopy reveals new variables influencing diagnosis Rheumatology (IF 4.7) Pub Date : 2025-02-07 Gema M Lledó-Ibáñez, Luis Sáez Comet, Mayka Freire Dapena, Miguel Mesa Navas, Miguel Martín Cascón, Alfredo Guillén del Castillo, Carmen Pilar Simeon, Elena Martinez Robles, José Todolí Parra, Diana Cristina Varela, Génesis Maldonado, Adela Marín, Laura Pérez Abad, Jimena Aramburu, Laura Vela, Eduardo Ramos Ibáñez, Borja del Carmelo Gracia Tello
Objectives Nailfold videocapillaroscopy (NVC) is the gold standard for diagnosing systemic sclerosis (SSc) and differentiating primary from secondary Raynaud's phenomenon. The CAPI-Score algorithm, designed for simplicity, classifies capillaroscopy scleroderma patterns (CSPs) using a limited number of capillary variables. This study aims to develop a more advanced machine learning (ML) model to improve
-
Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD) Rheumatology (IF 4.7) Pub Date : 2025-02-07 Benjamin Thoreau, Arthur Renaud, Philippe Chafey, Guilhem Clary, Morgane Le Gall, Cédric Broussard, Odile Launay, David Launay, Eric Hachulla, Christophe Deligny, Alban-Elouen Baruteau, Anaïs Vallet-Pichard, Benjamin Chaigne, Azzeddine Yaici, Olivier Sitbon, David Montani, Marc Humbert, Luc Mouthon
Objectives Pulmonary arterial hypertension (PAH) is a rare disease that may be associated with connective tissue diseases (CTD). Anti-fibroblast (AFA) and anti-endothelial cell autoantibodies (AECA) have been identified in idiopathic and systemic sclerosis (SSc)-associated PAH. The aim was to identify autoantibodies discriminating for PAH associated with systemic lupus erythematosus (SLE), mixed connective
-
Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active active rheumatoid arthritis Rheumatology (IF 4.7) Pub Date : 2025-02-07 Lin Qiao, Jiankang Hu, Daming Ou, Mixia Liu, Xiaofei Shi, Xiaomei Li, Rui Wu, Liyun Zhang, Yuan Liu, Changhong Xiao, Zili Fu, Jin Lin, Rongsheng Wang, Dongmei Zhou, Jing Yu, JingChun Jin, Shulin Song, Lin Tang, Hongsheng Sun, Yuanyuan Yin, Xiaofeng Zeng
Objectives This study aimed to compare the efficacy and safety of subcutaneous methotrexate (SC MTX) and oral MTX (OR MTX) in treating Chinese patients with active rheumatoid arthritis (RA). Methods This study included patients with active RA in China. All patients were randomly assigned to receive SC MTX or OR MTX. The primary end point was Disease Activity Score-28 for erythrocyte sedimentation rate
-
Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study Rheumatology (IF 4.7) Pub Date : 2025-02-05 Christina Charles-Schoeman, Joachim Schessl, Zsuzsanna Bata-Csörgő, Mazen M Dimachkie, Zoltan Griger, Sergey Moiseev, Chester V Oddis, Elena Schiopu, Jiri Vencovský, Elisabeth Clodi, Todd Levine, Rohit Aggarwal
Objectives The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM. Methods ProDERM was a prospective, randomised, placebo-controlled study of DM patients. For Weeks 0–16, patients received 2.0 g/kg IVIg (Octagam, 10%)
-
Towards the definition of disease phenotypes in pediatric SAPHO syndrome: a national multicentric study. Rheumatology (IF 4.7) Pub Date : 2025-02-05 Caterina Matucci-Cerinic,Anna Attico,Clara Malattia,Alessandro Consolaro,Silvia Rosina,Luciana Breda,Saverio La Bella,Marco Cattalini,Francesca Ricci,Giovanni Conti,Adele Civino,Letizia Baldini,Francesco Licciardi,Antonella Insalaco,Francesco La Torre,Serena Pastore,Giovanni Filocamo,Gisella Beatrice Beretta,Francesca Biscaro,Angela Miniaci,Gabriele Simonini,Edoardo Marrani,Angela Pistorio,Nicolino
OBJECTIVES To confirm the presence of different disease phenotypes of pediatric SAPHO syndrome (pSAPHO) based on their skin manifestations in a large cohort of Italian patients. METHODS pSAPHO were enrolled in the Eurofever Registry and the data retrospectively analysed. Patients were divided depending on their skin manifestations into an Acne-Hidradenitis suppurativa (HS) group and a Palmoplantar
-
Anti-citrullinated procollagen C-endopeptidase enhancer antibody: a potential biomarker for seronegative rheumatoid arthritis. Rheumatology (IF 4.7) Pub Date : 2025-02-05 Hongying Lin,Yang Xie,Xihua Wei,Chaonan Wei,Zhanguo Li,Fanlei Hu
OBJECTIVES Although with great advances, the biomarkers used in the diagnosis of rheumatoid arthritis (RA) are still challenging, especially in seronegative RA. Recently, procollagen C-endopeptidase enhancer (PCOLCE) was revealed as a potential autoantigen of seronegative RA by our group. This study aimed to further analyze the B cell autoantigenic epitopes of PCOLCE and the diagnostic value of its
-
A Phase 2 randomised trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis. Rheumatology (IF 4.7) Pub Date : 2025-02-05 Christopher P Denton,Otylia Kowal-Bielecka,Susanna M Proudman,Marzena Olesińska,Margitta Worm,Nicoletta Del Papa,Marco Matucci-Cerinic,Jana Radewonuk,Jeanine Jochems,Adrian Panaite,Amgad Shebl,Anna Krupa,Yannick Allanore,Jutta H Hofmann,Maria J Gasior
OBJECTIVES The primary objective was the safety of subcutaneous immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with diffuse cutaneous systemic sclerosis (dcSSc). Secondary objectives included pharmacokinetics and relative bioavailability of IgPro20, and safety and pharmacokinetics of intravenous immunoglobulin, IgPro10 (Privigen, CSL Behring). METHODS In this prospective, multicentre, randomised
-
Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients Rheumatology (IF 4.7) Pub Date : 2025-02-04 Chandni Sarker, Andrea L Jorgensen, Kukatharmini Tharmaratnam, Eslam Al-Abadi, Kate Armon, Kathryn Bailey, Marek Bohm, Mary Brennan, Coziana Ciurtin, Janet Gardner-Medwin, Daniel P Hawley, Alison Kinder, Alice Leahy, Gulshan Malik, Zoe McLaren, Elena Moraitis, Ellen Mosley, Athimalaipet V Ramanan, Satyapal Rangaraj, Annie Ratcliffe, Philip Riley, Heather Rostron, Ethan S Sen, Christian M Hedrich, Michael
Objectives To validate novel childhood-onset systemic lupus erythematosus (cSLE) T2T targets including Childhood Lupus Low Disease Activity State (cLLDAS), cSLE Clinical Remission on steroids (cCR), and cSLE Clinical Remission off steroids (cCR-0), as compared with adult-onset SLE (aSLE) targets. Methods Attainment of the aforementioned cSLE-specific and aSLE-specific targets (LLDAS, DORIS 2021 Remission)
-
Comment on: Renal Arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis: Reply. Rheumatology (IF 4.7) Pub Date : 2025-02-04 Shivani Garg,Brad Rovin,Amish N Raval,Christie M Bartels
-
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry) Rheumatology (IF 4.7) Pub Date : 2025-02-03 Hirofumi Shoda, Toshihiro Matsui, Shigeto Tohma, Tetsuji Sawada
Objective Patient-reported outcomes (PROs) should be regarded as an important factor in the management of rheumatic diseases. The Patient-based disease activity score (PDAS) was developed as a clinically reliable composite measure for evaluating PROs in rheumatoid arthritis (RA) patients. To replicate and further characterize PDAS, we analyzed PDAS and its clinical relevancy in the National Database
-
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study Rheumatology (IF 4.7) Pub Date : 2025-02-03 Ricarda Neubauer, Florian Recker, Claus-Juergen Bauer, Simon Petzinna, Pantelis Karakostas, Charlotte Behning, Valentin Sebastian Schäfer
Objectives Despite growing interest in musculoskeletal ultrasound (MSUS), training opportunities are often limited due to staff shortages and disbalances of expertise between rural and urban areas. Teledidactic approaches have the potential to expand access to training opportunities. This study aims to compare the effectiveness of teledidactic peer-tutored MSUS training to a conventional approach.
-
Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies related interstitial lung disease. Rheumatology (IF 4.7) Pub Date : 2025-02-03 Kamaree J R Harris,Erica A Ludtke,Blaire Goldberg,Natalie N McCall,Justin C Hewlett,Erin M Wilfong
OBJECTIVES Calcineurin inhibitors are commonly used to treat idiopathic inflammatory myopathies associated interstitial lung disease (IIM-ILD) in Asia but not in the U.S. Here, we evaluate the efficacy of tacrolimus (TAC) as first-line immunosuppressive therapy in a U.S cohort of IIM-ILD. METHODS This retrospective, single-centre cohort study evaluated the change in absolute forced vital capacity (FVCabs)
-
Association between large vessel vasculitis and inflammatory bowel disease: a case-control study Rheumatology (IF 4.7) Pub Date : 2025-02-03 François Maillet, Yann Nguyen, Olivier Espitia, Laurent Perard, Carlo Salvarani, Etienne Rivière, Dieynaba Ndiaye, Cécile-Audrey Durel, Philippe Guilpain, Luc Mouthon, Anna Kernder, Javier Loricera, Pascal Cohen, Isabelle Melki, Claire de Moreuil, Nicolas Limal, Arsène Mékinian, Nathalie Costedoat-Chalumeau, Nathalie Morel, Jonathan Boutemy, Loïc Raffray, Jean-Sébastien Allain, Valérie Devauchelle
Objectives To describe the characteristics and outcome of patients with the association of large vessel vasculitis (LVV, Takayasu arteritis [TA] or GCA) and IBD. Methods An observational, multicentre, retrospective case-control study. Cases were LVV-IBD patients from European countries, whereas controls had isolated LVV (iLVV). Results A total of 39 TA-IBD and 12 GCA-IBD cases were enrolled, compared
-
Comment on: Vasculitis associated with VEXAS syndrome. Rheumatology (IF 4.7) Pub Date : 2025-02-03 Riccardo Bixio,Roberto Padoan
-
The role of prokinetics in managing gastrointestinal involvement in systemic sclerosis: a systematic literature review Rheumatology (IF 4.7) Pub Date : 2025-02-01 Alberto Ezquerra-Durán, Luis G Alcala-Gonzalez, Alfredo Guillen-del-Castillo, Carmen P Simeón-Aznar, Elizabeth Barba, Carolina Malagelada, Michael Hughes, Zsuzsanna H McMahan
Objectives Gastrointestinal involvement (GI) in systemic sclerosis (SSc) is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility. Methods Studies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically
-
Towards better personalised care in rheumatoid arthritis. Rheumatology (IF 4.7) Pub Date : 2025-01-30 Peter C Taylor
-
Incidence of ANCA associated vasculitis and polyarteritis nodosa in Norfolk, UK, from 2011-2020 Rheumatology (IF 4.7) Pub Date : 2025-01-30 Sarah Fordham, Karen Ashurst, Alice Bartoletti, Fiona L Coath, Georgina Ducker, Ajay Kamath, Warda Mushtaq, Hassan Naeem, Isabelle Nicholls, Claire Sheehy, Katherine Sisson, Richard Watts, Chetan B Mukhtyar
Objective To report the annual and age-specific incidence of ANCA associated vasculitis and polyarteritis nodosa in the adult population of Norfolk County, UK. Methods Individuals newly diagnosed with ANCA associated vasculitis or polyarteritis nodosa between 1st Jan 2011 and 31st December 2020, residing in the postal areas of NR1-NR30 were included. Patients were classified according to the European
-
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus Rheumatology (IF 4.7) Pub Date : 2025-01-30 Sisi Yang, Yuanyuan Zhang, Ziliang Ye, Yanjun Zhang, Xiaoqin Gan, Yu Huang, Hao Xiang, Yiting Wu, Yiwei Zhang, Xianhui Qin
Objectives The relationship between proteomic profiles and incident systemic lupus erythematosus (SLE) remains unclear. We aimed to identify candidate plasma proteins for SLE risk in women, discover potential treatment targets for SLE, and develop and validate a protein-based prediction model for SLE risk. Methods 28 220 women from the UK Biobank were randomly split into training (70%) and testing
-
A comparative analysis of risk stratification tools in systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis. Rheumatology (IF 4.7) Pub Date : 2025-01-29 Hilde Jenssen Bjørkekjær,Cosimo Bruni,Kaspar Broch,Cathrine Brunborg,Patricia E Carreira,Paolo Airò,Carmen Pilar Simeón-Aznar,Marie-Elise Truchetet,Alessandro Giollo,Alexandra Balbir-Gurman,Mickael Martin,Christopher P Denton,Armando Gabrielli,Francesco Del Galdo,Madelon C Vonk,Håvard Fretheim,Helle Bitter,Øyvind Midtvedt,Arne Andreassen,Sverre Høie,Yoshiya Tanaka,Gabriela Riemekasten,Ulf Müller-Ladner
OBJECTIVES The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) Guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with systemic sclerosis (SSc)-associated PAH remains unclear. Our objective was to identify the most accurate approach for
-
Performance of spondyloarthritis-specific health utilities based on ASAS Health Index: an ancillary analysis from ASAS-HI validation study. Rheumatology (IF 4.7) Pub Date : 2025-01-29 Omar-Javier Calixto,Uta Kiltz,Wilson Bautista-Molano,Annelies Boonen,Sander van Kuijk,Ivette Essers,Désirée van der Heijde,Juergen Braun,Xenofon Baraliakos
OBJECTIVES To compare the utility values of Spondyloarthritis (SpA)-specific ASAS Health Index (U-ASAS-HI) to generic utilities and to understand the contribution of health outcomes, personal- and country-level factors to the U-ASAS-HI. METHODS Ancillary analysis of the ASAS-HI international validation study. SpA patients who completed the ASAS-HI, 5-level EuroQol-5D (EQ-5D-5L) and Short Form-36 (SF-36)
-
Cross-trait GWAS in COVID-19 and systemic sclerosis reveals novel genes implicated in fibrotic and inflammation pathways. Rheumatology (IF 4.7) Pub Date : 2025-01-29 Carlos Rosa-Baez,Gonzalo Borrego-Yaniz,Inmaculada Rodriguez-Martin,Martin Kerick,Marialbert Acosta-Herrera,Javier Martín,Lourdes Ortiz-Fernández
OBJECTIVES COVID-19 and systemic sclerosis (SSc) share multiple similarities in their clinical manifestations, alterations in immune response, and therapeutic options. These resemblances have also been identified in other immune-mediated inflammatory diseases where a common genetic component has been found. Thus, we decided to evaluate for the first time this shared genetic architecture with SSc. METHODS
-
Foot peripheral sensory neuropathy: a frequent disabling manifestation in systemic sclerosis. Rheumatology (IF 4.7) Pub Date : 2025-01-29 Begonya Alcacer-Pitarch,Marco Di Battista,Anthony C Redmond,Anne-Maree Keenan,Stefano Di Donato,Maya H Buch,Francesco Del Galdo
OBJECTIVES Peripheral Sensory Neuropathy (PSN) is an under-recognized feature in systemic sclerosis (SSc). Moreover, SSc foot involvement is frequent but poorly investigated. We aimed to provide a detailed characterization of foot PSN in a large cohort of SSc patients, describing its associations with disease-specific features, physical disability, and Quality of Life (QoL). METHODS SSc patients and
-
Tofacitinib Treatment for Active Dermatomyositis and Anti-synthetase Syndrome: A Prospective Cohort Pilot Study Rheumatology (IF 4.7) Pub Date : 2025-01-28 Xiaoyan Xing, Qinghong Liu, Naidi Wang, Kai Zhang, Wanxing Mo, Liang Zhao, Jian Zhang, Ke Ma, Xuyang Zhao, Dan Lu, Yuhui Li, Jing He
Objectives The objective of this study was to evaluate the efficacy and safety of tofacitinib in the treatment of active dermatomyositis (DM) and anti-synthetase syndrome (ASS). Methods Tofacitinib was administered at a dose of 5 mg twice daily to patients who exhibited inadequate response to conventional treatments. The primary end point was the reduction of T follicular helper (Tfh) cells at week
-
A predictive model based on the gut microbiota improves the diagnostic effect in patients with rheumatoid arthritis Rheumatology (IF 4.7) Pub Date : 2025-01-28 Qi Wang, Chen-Long Li, Si-Yuan Yu, Hui-Jing Dong, Lei Yang, Yang Liu, Pei-Feng He, Sheng-Xiao Zhang, Qi Yu
Objectives Rheumatoid arthritis (RA) is a chronic, destructive autoimmune disorder predominantly targeting the joints, with gut microbiota dysbiosis being intricately associated with its progression. The aim of the present study is to develop effective early diagnostic methods for early RA based on gut microbiota. Methods A cohort comprising 262 RA patients and 475 healthy controls (HCs) was recruited
-
Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology outpatient care in the US Rheumatology (IF 4.7) Pub Date : 2025-01-28 Erin E Blanchard, Allyson G Hall, Ezra Gore, Parvaneh Yaghoubi Jami, Aizhan Karabukayeva, Larry R Hearld, Shelby Gontarz, Jasvinder A Singh
Objective This study investigates the barriers and facilitators to sustaining a decision aid (DA) tool for patients with systemic lupus erythematosus (SLE) in routine rheumatology outpatient care across the U.S. The DA was initially developed for assisting Patients with SLE in making informed medication choices by providing personalized information on their treatment process. Methods We conducted semi-structured
-
A challenging case of limb autoamputation. Rheumatology (IF 4.7) Pub Date : 2025-01-28 Emil Aliyev,İsmahan Celep,Veysel Cam,Seza Ozen,Erdal Sag
-
Improving Outcomes in VEXAS Syndrome: The Need for Prospective Data. Rheumatology (IF 4.7) Pub Date : 2025-01-25 Jerome Hadjadj,David B Beck
-
Development of START, a novel multimedia-based symptom appraisal tool for autoimmune rheumatic diseases Rheumatology (IF 4.7) Pub Date : 2025-01-25 Ling Xiang, Andrea HL Low, Ying Ying Leung, Warren Fong, Tang Ching Lau, Dow Rhoon Koh, Sungwon Yoon, Julian Thumboo
Objectives To facilitate earlier diagnosis of autoimmune rheumatic diseases (ARDs), we aimed to 1) develop START, a novel multimedia-based symptom appraisal tool for ARDs and 2) pilot test START among established ARD cases and non-ARD controls. Methods We developed START using a social cognitive theory-based theoretical framework and consensus-based lists of ARDs and manifestations from our previous
-
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease Rheumatology (IF 4.7) Pub Date : 2025-01-25 Yusuke Yoshimura, Masayuki Yamanouchi, Ryo Koizumi, Hiroki Mizuno, Yuki Oba, Shigekazu Kurihara, Tatsuya Suwabe, Susumu Tsunoda, Ayumi Kishioka, Toshihiro Takeuchi, Hikaru Tanimizu, Hisashi Kamido, Masatoshi Yoshimoto, Hisashi Sugimoto, Daisuke Ikuma, Kiho Tanaka, Noriko Inoue, Akinari Sekine, Eiko Hasegawa, Takehiko Wada, Yoshifumi Ubara, Naoki Sawa
Objectives To evaluate the efficacy and safety of first-line targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in patients with rheumatoid arthritis (RA) and chronic kidney disease (CKD). Methods This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs
-
Predictive value of insulin resistance metabolic score for cardiovascular disease in Chinese arthritis patients: a prospective cohort study Rheumatology (IF 4.7) Pub Date : 2025-01-25 Wen-kai Ke, Ling-ling Xu, Ni Luo
Objectives Although patients with arthritis have significantly increased cardiovascular disease (CVD) risk, effective prediction tools remain limited. This study aimed to evaluate the predictive value of the Metabolic Score for Insulin Resistance (METS-IR) for CVD events among Chinese patients with arthritis. Methods Using data from the China Health and Retirement Longitudinal Study (CHARLS), we conducted
-
Imaging tests as predictors of progression to rheumatoid arthritis in clinically suspect arthralgia: A systematic review & meta-analysis Rheumatology (IF 4.7) Pub Date : 2025-01-25 Ankita Gupta, Sulaiman Anis, Paola de Pablo
Objectives To determine and compare the diagnostic accuracy of imaging tests for the prediction of RA progression in people with inflammatory joint pain or CSA. Methods We searched MEDLINE, Embase and Web of Science from 1987 to March 2024. Studies evaluating any imaging tests in participants with inflammatory joint pain or CSA, without clinical synovitis were eligible. Reference standards included
-
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea Rheumatology (IF 4.7) Pub Date : 2025-01-24 Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Thomas Paul, Hyerim Jin, Youkyung Lee, Min-Chan Park
Objective To describe the incidence rates of inflammatory bowel disease (IBD) and tuberculosis (TB) in Korean patients with ankylosing spondylitis receiving biologics. Methods Data from a Korean claims database between 2010 and 2021 was used to calculate crude incidence rates of TB and IBD using number of events and total patient-years (PYs). Results Overall, 43 643 and 43 396 patients were included
-
Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study. Rheumatology (IF 4.7) Pub Date : 2025-01-23 Lucas Maisonobe,Anne-Sophie Korganow,Alvise Berti,Alban Deroux,Nicolas Dupin,Selim Aractingi,Giacomo Emmi,Frederic Vandergheynst,Marc Fabre,Nicolas Kluger,Marielle Roux,Noémie Abisror,Audrey Benyamine,Giulia Cassone,François Chasset,Marie-Sylvie Doutre,Aurélie Foucher,Caroline Freguin,Delphine Gobert,Yannick Gombeir,José Hernandez-Rodriguez,Noémie Legouellec,Anne-Lise Pinault,Dimitri Titeca,Marie Jachiet
OBJECTIVES Urticarial vasculitis (UV) is characterized by atypical urticarial lesions and leukocytoclastic vasculitis, sometimes with extracutaneous manifestations. First-line treatment is based on colchicine, hydroxychloroquine, dapsone or low-dose glucocorticoids. In refractory forms, the use of biologics has been anecdotally described as potentially effective. We aimed to describe the efficacy and
-
Tissue degrading and remodelling molecules in giant cell arteritis Rheumatology (IF 4.7) Pub Date : 2025-01-22 Nobumasa Watanabe, Yuichiro Hara, Yasumasa Nishito, Mai Kounoe, Kazunari Sekiyama, Eisuke Takamasu, Takayasu Kise, Naofumi Chinen, Kota Shimada, Makoto Sugihara, Hideya Kawaji
Objectives GCA is a granulomatous vasculitis affecting large vessels, leading to intimal occlusion accompanied by the accumulation of myofibroblasts. Histopathologically, GCA is characterized by destruction of the tunica media and hypertrophy of the intima with invasion of activated CD4+ T cells, macrophages and multinucleated giant cells (MNGCs). Despite these well-defined histopathological features
-
In clinical hand osteoarthritis research, self-reported pain questionnaires do not reflect the patient experience Rheumatology (IF 4.7) Pub Date : 2025-01-21 Coen van der Meulen, Lotte A van de Stadt, Féline P B Kroon, Marieke Niesters, Frits R Rosendaal, Margreet Kloppenburg
Objective Pain in hand osteoarthritis (OA) is evaluated with repeated pain questionnaires. It is unclear whether these questionnaires adequately capture changes in pain recalled by patients. This study investigated whether changes on pain questionnaires (real-time evaluation) correspond to recalled pain. Methods Data from hand OA patients from the HOSTAS cohort (four one-yearly) and HOPE trial (one
-
Prediction of scleroderma renal crisis in patients of systemic sclerosis: insight from the CRDC cohort study Rheumatology (IF 4.7) Pub Date : 2025-01-21 Haochen Huang, Shihan Xu, Hongbin Li, Xinwang Duan, Min Hui, Jiaxin Zhou, Ling-ling Zhang, Mengtao Li, Xiaofeng Zeng, Dong Xu
Objective Early personalized identification of systemic sclerosis (SSc) patients at risk for scleroderma renal crisis (SRC) can help provide better treatment and improve outcomes. This study aimed to create and validate a new multi-predictor nomogram to predict SRC risk and compare it to an existing model. Methods A retrospective multicentre observational study was conducted using clinical data from
-
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still's Disease Registry Rheumatology (IF 4.7) Pub Date : 2025-01-20 Piero Ruscitti, Antonio Vitale, Ilenia Di Cola, Valeria Caggiano, Pierpaolo Palumbo, Ernesto Di Cesare, Andrea Hinojosa-Azaola, Jiram Torres-Ruiz, Guillermo Arturo Guaracha-Basañez, Eduardo Martín-Nares, Giuseppe Lopalco, Maria Morrone, Florenzo Iannone, Henrique A Mayrink Giardini, Rafael Alves Cordeiro, Isabele Parente de Brito Antonelli, Onorina Berardicurti, Luca Navarini, Francesco Ciccia, Maria
Objectives To assess the lung involvement in patients with Still’s disease, an inflammatory disease assessing both children and adults. To exploit possible associated factors for parenchymal lung involvement in these patients. Methods A multicentre observational study was arranged assessing consecutive patients with Still’s disease characterized by the lung involvement among those included in the AIDA
-
Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year longitudinal cohort Rheumatology (IF 4.7) Pub Date : 2025-01-20 Shirley CW Chan, Yao Lei, Desmond YH Yap, Pamela PW Lee, Wai Ming Lai, Shirley KY Ying, Alexander MH Leung, Chi Chiu Mok, Ka Lai Lee, Chak Sing Lau, Wanling Yang, Philip H Li
Objective Systemic lupus erythematosus (SLE) is a heterogeneous disease which manifests as different subphenotypes. Distinct subphenotypes, such as lupus nephritis (LN), have been associated with increased genetic risk, but prior studies have been limited by cross-sectional and imprecisely subphenotyped cohorts. This study investigated the genetic basis for LN using a longitudinal cohort of distinctly
-
Circulating secretory component-containing anti-citrullinated protein antibodies prior to symptom onset in rheumatoid arthritis Rheumatology (IF 4.7) Pub Date : 2025-01-17 Klara Martinsson, Linda Johansson, Alf Kastbom, Solbritt Rantapää-Dahlqvist
Objectives To investigate the occurrence and dynamics of secretory component-containing antibodies towards citrullinated proteins (SC ACPA) in plasma from pre-symptomatic individuals subsequently developing rheumatoid arthritis (RA). Methods We studied 319 individuals who had donated plasma prior to RA onset (median predating time 4.7 years), whereof 181 also donated samples after diagnosis. One hundred
-
Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria Rheumatology (IF 4.7) Pub Date : 2025-01-16 Yuewen Lu, Li Tan, Wang Xiang, Yuting Fan, Jianwen Yu, Xin Wang, Hongjian Ye, Zhong Zhong, Haishan Wu, Ruihan Tang, Xi Xia, Wei Chen
Objectives Proliferative lupus nephritis (LN) is not uncommon in individuals with proteinuria < 0.5 g/24h, highlighting the importance of predicting proliferative nephritis for effective clinical management. We aimed to develop a predictive model for proliferative nephritis in this population. Methods The enrolled 671 biopsy-proven LN patients were divided into low-level proteinuria (< 0.5 g/24 h)
-
Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease Rheumatology (IF 4.7) Pub Date : 2025-01-16 Corrado Campochiaro, Alessandro Tomelleri, Francesco Catamerò, Francesco Pegoraro, Augusto Vaglio, Lorenzo Dagna
Objective Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients with ECD has led to the introduction of targeted therapies. The most commonly used targeted therapies are BRAF- and MEK-inhibitors, which are highly effective but also carry
-
Comment on: Caffeine improves systemic lupus erythematosus endothelial dysfunction by promoting endothelial progenitor cells survival: Reply. Rheumatology (IF 4.7) Pub Date : 2025-01-15 Valeria Orefice,Fulvia Ceccarelli,Cristiano Alessandri,Fabrizio Conti
-
OP01 MRI is of utility in the evaluation of disease activity in axial Spondyloarthritis- data from a tertiary rheumatology centre Rheumatology (IF 4.7) Pub Date : 2025-01-13 Jake Weddell, Rahul Shah, Lara Rossi, Phil Robinson, Andrew Barr, Claire Vandevelde, Jane E Freeston, Dennis McGonagle, Helena Marzo-Ortega
Background Assessing disease activity in axial spondyloarthritis (axSpA) is challenging, with heavy reliance on patient reported outcome measures. These measures are subjective and can be influenced by non-inflammatory causes of symptoms, potentially resulting in inappropriate changes to therapy. Despite its unanimous use in the diagnosis of axSpA, the most recent EULAR/ASAS guidelines do not support
-
Empowering people to take control of their persistent low back pain through public awareness campaigning. Rheumatology (IF 4.7) Pub Date : 2025-01-12 Joe Eddison,Thomas A Ingram,Clare Clark,Jill Hamilton,Raj Sengupta,Karl Gaffney,Dale Webb
-
The clinical characteristics and treatment outcomes of patients with systemic polyarteritis nodosa (PAN): a single centre study from India Rheumatology (IF 4.7) Pub Date : 2025-01-11 Avanish Jha, Chitra R, Bijesh Yadav, Betty Simon, Ashish Mathew, John Mathew, Meera Thomas, Ruchika Goel
Objectives To describe the clinical profile and compare the long-term outcomes of patients with S-PAN treated with various treatment regimens at our centre in the last 2 decades. Methods Data regarding clinical presentation, treatment allocation, relapses and outcomes of patients fulfilling American College of Rheumatology (ACR) 1990 criteria for PAN in the last 2 decades were recorded from electronic
-
Poor Prognostic Factors and Unmet Needs in Rheumatoid Arthritis Rheumatology (IF 4.7) Pub Date : 2025-01-11 Josef S Smolen
Prognostic factors in rheumatoid arthritis relate to several aspects, such as prediction of joint damage and loss of function or prediction of response to a particular therapy. Since many decades, it is well established that high disease activity, especially exemplified by swollen joint counts and acute phase reactants, is associated with progression of joint damage. In addition, rheumatoid factor
-
Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies Rheumatology (IF 4.7) Pub Date : 2025-01-10 Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Filip Van den Bosch, Marina Magrey, Walter P Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Tom Vaux, Chetan Prajapati, Myriam Manente, Alexander Marten, Lianne S Gensler
Objectives Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years. Methods Patients completing week 52 in the phase 3 studies
-
Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events were Infrequent During Clinical Trials of Pegloticase Rheumatology (IF 4.7) Pub Date : 2025-01-10 Orrin M Troum, Mai Duong, Katie Obermeyer, Lissa Padnick-Silver, Brian LaMoreaux
Objectives Long-term maintenance of serum urate (SU) levels <6 mg/dl reduces gout flare frequency. However, urate-lowering therapy (ULT) initiation can induce gout flare. The incidence of thromboembolic (TE) and cardiovascular (CV) events has been shown to increase in the 30 and 120 days following gout flare, respectively; therefore, the question of ULT initiation increasing patient risk for CV/TE
-
Clinical Characteristics of Primary and Overlap Sjögren's Syndrome-Associated Pulmonary Arterial Hypertension: A Multicenter Retrospective Study Rheumatology (IF 4.7) Pub Date : 2025-01-10 Xiaoxuan Sun, Yixin Zhang, Ting Liu, Hang Zhang, Zu Beibei, Lei Zhou, Qiang Wang, Miaojia Zhang
Objective To explore the clinical characteristics and risk factors for adverse outcomes in patients with Sjögren’s Syndrome-associated pulmonary arterial hypertension (SS-PAH). Methods A retrospective analysis was conducted on SS-PAH patients diagnosed by right heart catheterization (RHC) between March 2013 and March 2024 across four Chinese medical centers. Patients were categorized into primary SS-PAH
-
Anti-C1q antibodies in IgG4-related disease are common and associated with renal involvement and cutaneous small-vessel vasculitis Rheumatology (IF 4.7) Pub Date : 2025-01-09 Eduardo Martín-Nares, Carlos A Nuñez-Álvarez, Gabriela Hernández-Molina
Objectives To evaluate the prevalence and clinical associations of anti-C1q antibodies in IgG4-related disease (IgG4-RD), focusing on renal involvement and cutaneous small-vessel vasculitis (CSVV). Methods We enrolled patients who met the revised 2020 Comprehensive Diagnostic Criteria and/or the 2019 ACR/EULAR Classification Criteria for IgG4-RD. Variables included demographics, organ involvement,